Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Long-Term Investments (2017 - 2018)

Amicus Therapeutics filings provide 4 years of Long-Term Investments readings, the most recent being $13.8 million for Q2 2018.

  • On a quarterly basis, Long-Term Investments changed N/A to $13.8 million in Q2 2018 year-over-year; TTM through Jun 2018 was $13.8 million, a N/A change, with the full-year FY2015 number at $658000.0, down 96.23% from a year prior.
  • Long-Term Investments hit $13.8 million in Q2 2018 for Amicus Therapeutics, down from $42.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $42.7 million in Q1 2018 to a low of $482000.0 in Q2 2015.
  • Median Long-Term Investments over the past 4 years was $14.5 million (2017), compared with a mean of $13.6 million.
  • The widest YoY moves for Long-Term Investments: up 96.23% in 2015, down 96.23% in 2015.
  • Amicus Therapeutics' Long-Term Investments stood at $17.5 million in 2014, then crashed by 96.23% to $658000.0 in 2015, then surged by 2196.2% to $15.1 million in 2017, then dropped by 8.43% to $13.8 million in 2018.
  • The last three reported values for Long-Term Investments were $13.8 million (Q2 2018), $42.7 million (Q1 2018), and $15.1 million (Q3 2017) per Business Quant data.